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Protein degraders, also known as proteolysis targeting chimeras (PROTACs), are bifunctional 
small molecules that bring an E3 ubiquitin ligase and a protein of interest (POI) into 
proximity, thus promoting ubiquitination and degradation of the targeted POI [1-3]. Despite 
their great promise as next-generation pharmaceutical drugs, the development of new 
PROTACs is challenged by the complexity of the system, which involves binary and ternary 
interactions between components. Here, we demonstrate the strength of native mass 
spectrometry (nMS), a label-free technique, to provide novel insight into PROTAC-mediated 
protein interactions. We show that nMS can monitor the formation of ternary E3-PROTAC-
POI complexes and detect various intermediate species in a single experiment. A unique 
benefit of the method is its ability to reveal preferentially formed E3-PROTAC-POI 
combinations in competition experiments with multiple substrate proteins, thereby 
positioning it as an ideal high-throughput screening strategy during the development of new 
PROTACs.  
The development of PROTACs, small molecule “protein degraders” (Fig. 1a), is an emerging 
strategy in drug discovery, having major advantages over traditional small molecule inhibitors. 
PROTACs eliminate a target protein rather than inhibit it and function in a catalytic manner, 
requiring sub-stoichiometric amounts to achieve efficiency [4]. Moreover, PROTACs are 
applicable to a wider spectrum of proteins since degradation is not limited to a specific 
functional domain or active site [5]. To date, protein degraders have been developed against 
a variety of medically relevant proteins, such as the tumorigenic Androgen Receptor and 
Estrogen Receptor, as explored in first clinical trials [5-10]. In order to realise the full potential 
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of protein degraders, methods have been developed to address the complex kinetics of multi-
component PROTAC systems, which comprise various intermediate states [11-13]. Notably, 
the analysis of ternary interactions requires certain approximations to overcome the 
limitations of traditional biophysical techniques and always demands multiple experiments to 
estimate the basic kinetic parameters of the PROTAC system of interest. 
With the use of nano-electrospray ionisation (nESI) [14], protein complexes can retain their 
native topology and stoichiometry during transfer from solution into the gas phase, making 
protein-protein and protein-ligand interactions amenable to MS analysis [15]. Key advantages 
of this “native MS” approach [16] include the label-free measurement of protein complexes 
and its capability to report on multiple binding stoichiometries present in dynamic protein 
mixtures, including molecular species populated to a low extent [15, 17-20]. For these reasons, 
we anticipated that nMS would be particularly applicable for the characterisation of PROTAC 
systems. It could complement quantitative biophysical methods such as isothermal titration 
calorimetry (ITC) and surface plasmon resonance (SPR) by analysing the E3, PROTAC and POI 
interplay in a single experiment (Fig. 1b). Here, we demonstrate that nMS can (1) report on 
the formation of E3-PROTAC-POI ternary complexes in a semi-quantitative manner, (2) 
delineate the binding specificity of a particular PROTAC molecule and (3) simultaneously 
measure PROTAC specificity to multiple substrate proteins in a single measurement. To this 
end, we used the two established PROTACs AT1 and MZ1, which target bromodomain-
containing proteins for degradation via the Von-Hippel-Lindau (VHL) E3 ligase, as model 
compounds. Specificity, affinity and degradation behaviour of AT1 and MZ1 towards different 
bromodomains has been well characterised [12, 21-23], providing an excellent test system to 
benchmark nMS as an analytical tool in PROTAC research. Substrate proteins investigated 
include the first and second bromodomains of Brd4 (Brd4BD1 and Brd4BD2), and the second 
bromodomain of Brd3 (Brd3BD2). E3, PROTAC (P) and substrate (S) combinations that were 
characterised by MS are summarised in Table 1, together with results from previous ITC and 
SPR analyses.  
We first tested the capability of nMS to resolve dimeric (E3:P, E3:S, P:S) and trimeric (E3:P:S) 
complexes present in the reaction mixture. This initial analysis was focussed on Brd4BD2 (S) 
and its interaction with the VHL/elongin-B/elongin-C complex (VCB, E3), with and without 
AT1/MZ1 (P). As reference, native mass spectra of VCB and Brd4BD2 (5 µM) were recorded 
separately, sprayed from 100 mM ammonium acetate, and 100mM ammonium acetate 
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containing 0.5% DMSO (Fig. S1 and S2), the latter condition used in all experiments monitoring 
complex formation. Expected and measured masses of each species are provided in Table S1. 
A native mass spectrum of a VCB and Brd4BD2 mixture (Fig. 1c) shows that no interaction 
occurs between the proteins in the absence of a PROTAC molecule. VCB presents in charge 
states [M+9H]9+ to [M+12H]12+, and Brd4BD2 presents in charge states [M+5H]5+ to [M+17H]17+, 
with most of the intensity in charge states [M+6H]6+ and [M+7H]7+. The inset shows the 
estimated fractional ratios of the integrated peaks corresponding to each species, calculated 
by summing the intensity of each charge state corresponding to a particular species, and 
normalised to the summed intensity of all annotated peaks in the spectrum. Upon the addition 
of 5 µM AT1 (1:1:1 ratio of E3:P:S), peaks are present at m/z ratios corresponding to that of 
the ternary Brd4BD2-AT1-VCB complex. Compared to the signal intensity of the ternary 
complex (0.25 of total intensity), signal corresponding to the binary VCB-AT1 species (E3:P) is 
in very low abundance (0.01), while the Brd4BD2-AT1 species (P:S) is not observed at all. When 
the AT1 concentration was increased to 10 µM (1:2:1 ratio of E3:P:S), the signal corresponding 
to the ternary complex becomes dominant (0.55), compared to VCB-AT1 (0.05) and Brd4BD2-
AT1 complexes (0.03) and the apo VCB (0.02). Only the signal corresponding to apo Brd4BD2 
remains relatively high (0.35). Interestingly, upon addition of AT1, the intensity of the 
[M+6H]6+ and [M+7H]7+ charge states become lower compared to the charge states [M+8H]8+ 
and above. These lower charge states correspond to a compact, folded conformation, with 
the higher charge states corresponding to an unfolded protein subpopulation [24, 25]. We can 
therefore infer that the folded conformation of Brd4BD2 is incorporated into the ternary 
complex, whilst the unfolded subpopulation remains isolated. Consistent with this, the 
Brd4BD2-AT1 binary complex is present only in [M+6H]6+ and [M+7H]7+, and no peaks are 
present corresponding to higher charge states. Distinguishing between folded and unfolded 
factions present in a substrate sample further highlights the potential of nMS in characterizing 
complex PROTAC reaction mixtures. To compare complex formation with a different PROTAC, 
equivalent measurements were carried out with MZ1 (Fig. S3). The overall distribution of 
binary and ternary complexes is similar to those formed with AT1, but in this case no binary 
complex between Brd4BD2 and MZ1 is observed, even at 10 µM MZ1 concentration. These data 
fit to the higher stability of ternary complex initiated by MZ1 relative to AT1, as determined 
by SPR measurements (Table 1). In sum, the initial MS measurements demonstrate the 
strength of nMS for the characterisation of protein complexes formed by PROTAC molecules, 
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providing a semi-quantitative description of the binding equilibrium between E3, substrate 
and PROTAC. Moreover, the method reveals characteristic differences in reaction 
intermediates formed with different PROTACs, implying mechanistic differences in ternary 
complex formation. 
To investigate whether nMS can report on the specificity of PROTACs for particular substrate 
proteins, we took advantage of the preference of AT1 to form ternary complexes with Brd4BD2 
over other bromodomain-containing proteins [12, 21, 22]. Spectra of a VCB:AT mixture with 
different bromodomain substrates Brd4BD2, Brd3BD2 and Brd4BD1 respectively, are shown in 
Fig. 2 a-c (spectra of isolated Brd4BD2, Brd3BD2 and Brd4BD1 in Fig. S2, Fig. S4 and Fig. S5). Owing 
to the different ionization efficiencies of the free substrates, we integrated the signal intensity 
of apo-VCB, the binary VCB-AT1 complex and the three ternary complexes. Comparing the 
relative amounts of ternary complexes reveals the preferential engagement of Brd4BD2 by 
VCB:AT1 (0.82), relative to Brd3BD2 (0.58) and Brd4BD1 (0.65). These data are consistent with 
previous ITC experiments, where VCB was mixed with saturated PROTAC-substrate complexes 
to estimate the Kd of ternary complex formation [21] (Table 1). Although nMS and ITC 
measurement predict slightly different preferences in binding Brd3BD2 and Brd4BD1, both 
methods highlight that the VCB:AT1 system most favourably forms a ternary complex with 
Brd4BD2. We next investigated the PROTAC MZ1, which binds all bromodomain substrates with 
higher affinity than AT1, but displaying less selectivity for Brd4BD2 (Fig. S9). In this case, the 
relative amounts of ternary complexes with Brd4BD2, Brd3BD2 and Brd4BD1 are 0.92, 0.83 and 
0.80, respectively, pointing to a similar stability of the formed complexes (triplicate 
measurements shown Fig. S10-12). For MZ1 the Kd values from ITC are 4 nM, 7 nM and 28 nM 
for Brd4BD2, Brd3BD2 and Brd4BD1, respectively, fitting nicely to the nMS data (Table 1). Taken 
together, the nMS data demonstrate the pronounced selectivity of AT1 towards Brd4BD2, 
whereas MZ1 is a less selective PROTAC targeting bromodomains. 
An additional question regarding the mechanism of PROTACs is whether they display 
cooperative behaviour. To address this point, we measured E3:AT1 and S:AT1 mixtures and 
compared the binary complex formation to ternary complex formation, using a cooperative 
(Brd4BD2) and a non-cooperative (Brd4BD1) substrate (Fig. S13). Binary complex formation of 
VCB:AT1 is low, below 0.2, and the binary complex formation of Brd4BD2:AT1 and Brd4BD1:AT1 
is roughly 0.5 in both cases. When the three components are mixed together, however, the 
ternary complex is formed to a much higher extent with Brd4BD2 (0.82) than Brd4BD1 (0.65), 
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hinting at cooperativity of this PROTAC system, as proposed by [21]. According to these data, 
nMS analysis allows, in addition to determining the most favoured ternary complexes, to 
distinguish differences in cooperativity between PROTAC systems. 
Finally, in order to take full advantage of the benefits of nMS over other biophysical methods, 
we applied our approach to a complex reaction mixture containing an E3, a PROTAC and 
multiple substrates. Since nMS was able to distinguish PROTAC specificity in separate 
experiments, we were curious to what extent PROTACs would recruit the bromodomains in a 
competition experiment that mimics the in vivo situation more closely. Ternary complex 
formation was measured using equimolar amounts of Brd4BD2, Brd3BD2 and Brd4BD1 and the 
PROTAC MZ1 that seemingly promotes ternary complex formation in a rather unselective 
manner (Fig. S9). Initially, an overall substrate concentration (S1+S2+S3) equimolar to that of 
VCB was used, thus avoiding competitive binding. In this case, the relative signal intensity of 
ternary complex incorporating Brd4BD2 is the highest, with that incorporating Brd3BD2 at a 
slightly lower intensity and that incorporating Brd4BD1 at an even lower intensity (Fig. 3a). 
When the substrate concentration is increased threefold, thereby increasing the competition 
for binding, the signal intensity of the Brd4BD2-containing ternary complex is more than three 
times higher than complexes containing Brd3BD2 and Brd4BD1 (Fig. 3b), clearly outcompeting 
the other substrates. Together, these data indicate that the competition experiment provides 
more detailed insight into complex formation than the separate experiments, revealing the 
preferentially formed ternary complex and thus best PROTAC substrate. The preference for 
Brd4BD2 observed by nMS fits to the increased half-life of the respective ternary complex 
(130s) as compared to that with Brd3BD2 (6s) and Brd4BD1 (<1s) (Table 1 and ref. [12]). In fact, 
the lower half-life of the complex with Brd3BD2 is thought to be the reason for the lower 
degradation efficiency of Brd3 with respect to Brd4 in cells, despite similar binding affinity [12, 
21, 22]. When the same MS experiments are performed with AT1, which has higher specificity 
for Brd4BD2, the signal intensity for the complex containing Brd4BD2 is higher than the other 
complexes, in both the low-competition and high-competition experiment (Fig. 3c and 
Fig. 3d). This reflects the preference of the formation of the VCB:AT1:Brd4BD2 complex over 
other substrate complexes. 
We next analyzed E3:P:S mixtures of even higher complexity, containing 5 bromodomain 
substrates and either MZ1 (Fig. 3e) or AT1 (Fig. 3f). Peaks can be separated for complexes 
containing Brd4BD2, Brd4BD1 and BrdT. The mass of Brd2BD2 is very close to that of Brd3BD2 (13 
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351 Da vs. 13 279 Da) and therefore complexes containing these proteins cannot be 
distinguished from one another. It is, however, clear from the spectra with both PROTACs that 
the complex containing Brd4BD2 has the highest intensity, inferring that this is the most 
favorable interaction. Additionally, the difference in intensity between Brd4BD2 and the next 
most intense peaks is bigger for the sample containing AT1 (Fig. 3f) with respect to MZ1 (Fig 
3e), further demonstrating the higher specificity of this PROTAC. Such nMS experiments would 
be highly informative when screening proteins that are recruited by a certain PROTAC. Even if 
not every protein can be distinguished, as is the case for Brd3BD2 and Brd2BD2, the number of 
potential interactors can be greatly reduced for further investigation. Measuring the substrate 
proteins in mixtures is more time-effective than separate measurements and has the added 
advantage of providing information on competition between substrates forming the ternary 
complexes. Given the remarkable resolution of nMS, even small size differences in POIs, for 
instance introduced by adding short peptide tags, could be resolved, allowing the analysis of 
even more complex substrate sets as in the current analysis.  
To conclude, we have demonstrated, for the first time, that nMS is an effective technique to 
investigate PROTAC-mediated protein complexes. We can determine differences in specificity 
of a PROTAC towards different proteins and can measure ternary complex formation of 
different substrates in a single experiment, which is highly beneficial in the generation of new 
PROTAC molecules. Whilst SPR and ITC remain the most appropriate methods for obtaining 
kinetic and thermodynamic data, we envision that nMS will become a popular tool in PROTAC 
development owing to its fast measurement time, straight-forward data analysis and ability 
to detect different species in equilibrium. Moreover, nMS bears the unique advantage to 
perform competition experiments, directly comparing potential substrates and various 
PROTACs to yield the most efficient degrading system. 
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Online Methods 
Protein expression and purification 
BRD2BD2 BRD3BD2,  BRDt, BRD4BD1 and BRD4BD2 were expressed and purified as described by 
Filippakopoulos et al. [26] with final concentrations of 10.2 mg/mL (10 mM Hepes, 500 mM 
NaCl, 5% Glycerin, pH 7,5), 16 mg/mL (25 mM Hepes, 150 mM NaCl, 5 mM DTT, pH 7,5) 39.5 
mg/mL (10 mM Hepes,   500 mM NaCl, 10 mM DTT,  5% Glycerin, pH 7,4), 13.4 mg/mL (50 mM 
Hepes, 500 mM NaCl, 5% Glycerin, pH 7,5) and 19 mg/mL (10 mM Hepes, 100 mM NaCl, 10 
mM DTT, pH 7,5) respectively. Human VHL (54–213), ElonginC (17–112) and ElonginB (1–104) 
were co-expressed as described previously [5].All protein sequences are provided in Table S2.  
Sample preparation for native MS experiments.  
PROTACs were provided in a 10mM solution in DMSO, which was diluted 100x in water (100 
µM, 1% DMSO). This was further diluted to 2x the working concentration using 1% DMSO in 
water, to ensure constant DMSO concentration across all experiments. Proteins were buffer 
exchanged into ammonium acetate using BioRad Micro Bio-Spin 6 Columns and the 
concentrations were measured with a Bradford Assay. Unless described otherwise, 20 µM 
substrate and 20 µM E3 ligase were mixed in an equimolar concentration (10 µM each) and 
added to an equivalent volume of PROTAC stock, to give final solution conditions of 5 µM 
substrate, 5 µM VCB, 5-10 µM PROTAC in 100 mM ammonium acetate, 0.5% DMSO.  
Mass spectrometry measurements.  
Native mass spectrometry experiments were carried out on a Synapt G2Si instrument (Waters, 
Manchester, UK) with a nanoelectrospray ionisation source. Mass calibration was performed 
by a separate infusion of NaI cluster ions. Solutions were ionised through a positive potential 
applied to metal-coated borosilicate capillaries (Thermo Scientific). The following instrument 
parameters were used for PROTAC complexes; capillary voltage 1.3 kV, sample cone voltage 
80 V, extractor source offset 60 V, source temperature 40 °C, trap gas 3 mL/min. For individual 
proteins, the capillary voltage was set to 1.1 kV, sample cone voltage 40V, extractor source 
offset 30V, source temperature 40  ̊C and trap gas 2 mL/ min. Data were processed using 
Masslynx V4.1 and GraphPad Prism 8.1.1. To determine the estimated ratio of signal 
corresponding to each species, the relative intensity of peaks involved in the comparison were 
summed, and the sum of peaks for a particular species was divided by the sum of the total 
peaks.  
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Figure 1 (a) Mechanism of targeted protein degradation by a proteolysis targeting chimera 
(PROTAC) molecule. The substrate protein is shown in blue and the E3 ligase in green. (b) 
Schematic of the native mass spectrometry (nMS) approach. (c-e) nESI-MS of Brd4BD2 (5 µM, 
15 036 Da) and VCB (5 µM, 41 376 Da) sprayed from ammonium acetate (100 mM, pH 6.8) 
and 0.5% DMSO at AT1 (971 Da) concentrations of 0 µM (c), 5 µM (d) and 10 µM (e). Insets 
show estimated relative signal intensity of integrated peaks corresponding to apo-Brd4BD2, 
binary AT1-Brd4BD2 complex, apo-VCB, binary AT1-VCB complex and ternary complex Brd4BD2-
AT1-VCB. Bar charts are representative of a single measurement, so no error bars are shown 
in this case. Expected and measured masses of each species are reported in Table S1. At an 
equimolar ratio, the signal intensity of Brd4BD2 is higher than that of VCB, likely due to higher 
ionisation efficiency as a result of its smaller mass and higher charge states. 
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Figure 2; nESI-MS of VCB (5 µM), AT1 (10 µM) and Brd4BD2 (5 µM, a), Brd3BD2 (5 µM, b) or 
Brd4BD1 (5 µM, c). Proteins are sprayed from a starting solution of ammonium acetate (100 
mM, pH 6.8) and 0.5% DMSO. Inset; estimated relative intensity of summed peaks 
corresponding to apo- VCB, binary AT1-VCB complex and ternary complex substrate-AT1-VCB. 
Samples were analysed in triplicate (see Fig. S6-8) and the error bars represent standard 
deviation of the relative peak intensity. Fractional intensity of signal corresponding to the 
ternary complex is shown, and values for other species can be found in Table 1. 
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Figure 3; nESI spectra of VCB, PROTAC and a mixture of Bromodomain substrates. (a) VCB (5 
µM), MZ1 (10 µM), equimolar mixture of Brd4BD2 (blue), Brd3BD2 (purple) and Brd4BD1 (red) 
(total Brd concentration 5 µM). (b) as a, but total Brd concentration 15 µM. (c, d) as a and b 
respectively, but PROTAC is AT1. (e) VCB (2.5uM), MZ1 (5uM), and a mixture of five 
Bromodomain substrates; Brd4BD2, Brd3BD2, Brd2BD2 (yellow), Brd4BD1, BrdT (cyan), total 
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substrate concentration 12.5 µM. (f) as e, but PROTAC is AT1. Peaks corresponding to the most 
intense species are labelled, and fully annotated versions are given in Fig S14.  
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  KD of VCB binding 
to [PROTAC + 
substrate]  
Cooperativity  t1/2 of 
ternary 
complex  
fraction of 
ternary 
complex 
  ITC [21] SPR [12] SPR [12] SPR [12] nMS 
PROTAC substrate      
AT1 Brd4BD1 390 nM 578 nM 0.2 <1s 0.65 ± 0.1 
AT1 Brd3BD2 79 nM 163 nM 0.7 3s 0.58 ± 0.07 
AT1 Brd4BD2 46 nM 24 nM 4.7 26s 0.82 ± 0.06 
MZ1 Brd4BD1 28nM 30nM 0.9 <1s 0.80 ± 0.06 
MZ1 Brd3BD2 7nM 8nM 3.6 6s 0.83 ± 0.05 
MZ1 Brd4BD2 4nM 1nM 22 130s 0.92 ± 0.03 
 
Table 1 Comparison of native MS data on ternary complex formation with literature values.  
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